The long noncoding RNA Meg3 mediates TLR4-induced inflammation in experimental obstructive nephropathy

Wai Han Yiu1, Sarah W Y Lok1, Rui Xue1

  • 1Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong.

Insights

Long noncoding RNA Meg3 promotes kidney inflammation and fibrosis in chronic kidney disease (CKD). Targeting Meg3 may offer a novel therapeutic strategy for TLR4-driven kidney injury.

Area of Science:

  • Nephrology
  • Molecular Biology
  • Immunology

Background:

  • Kidney inflammation drives chronic kidney disease (CKD) progression.
  • Toll-like receptor 4 (TLR4) signaling is implicated in kidney inflammation, but its regulatory mechanisms in tubular injury remain unclear.

Purpose of the Study:

  • To investigate the role of long noncoding RNA (lncRNA) Meg3 in TLR4-mediated kidney inflammation and fibrosis.
  • To elucidate the regulatory pathway involving Meg3 in tubular epithelial cells during kidney injury.

Main Methods:

  • Utilized tubule-specific TLR4 knockout mice to study obstruction-induced kidney injury.
  • Performed transcriptome analysis to identify differentially expressed lncRNAs.
  • Investigated Meg3 induction by lipopolysaccharide (LPS) in tubular epithelial cells via a p53-dependent pathway.
  • Assessed the effects of Meg3 silencing on inflammatory responses and kidney fibrosis in vitro and in vivo.

Main Results:

  • Tubule-specific deletion of TLR4 protected against kidney injury, reducing inflammation, macrophage infiltration, and fibrosis.
  • lncRNA Meg3 was significantly downregulated in the kidneys of TLR4 knockout mice.
  • Meg3 expression was induced by LPS in tubular cells through p53 signaling.
  • Meg3 silencing attenuated LPS-induced cytokine production (CCL-2, CXCL-2) and p38 MAPK activation, and ameliorated kidney fibrosis.

Conclusions:

  • lncRNA Meg3 plays a pro-inflammatory role in the progression of chronic kidney disease.
  • A novel regulatory pathway involving TLR4, p53, and Meg3 in tubular epithelial cells contributes to kidney inflammation and fibrosis.
  • Targeting lncRNA Meg3 represents a potential therapeutic strategy for TLR4-driven kidney diseases.